Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies.
about
Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan.Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.Donating blood for research: a potential method for enhancing customer satisfaction of permanently deferred blood donors.Refining the risk estimate for transfusion-transmission of occult hepatitis B virus.Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.Use of intravenous immunoglobulin in critically ill patients.A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.Community attitudes to remunerated blood donation in Australia: results from a national telephone survey.Modeling red cell procurement with both double-red-cell and whole-blood collection and the impact of European travel deferral on units available for transfusion.Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006.Prevalence of selected viral infections among temporarily deferred donors who returned to donate blood: American Red Cross blood donor study.Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia
P2860
Q24813256-FDF9070C-B3A0-4E26-B500-3F206CC7CFB9Q36078723-9795B942-0667-4241-852B-DDAEE0E92C21Q37609070-8C6F781B-5422-4EE0-AC94-EC5A7253D1A2Q39450759-2A70096C-B19E-458B-95A3-F5F41BB384A0Q40383406-36B7B72E-32CB-4BE6-929B-9D4D05358AE9Q40622701-34897B5C-B9C4-49D1-94C0-4E33E48751FBQ41667356-82B8B230-BD59-45FC-A8C6-7C32532DBC59Q42257442-CF8D2379-D471-42A7-A2AB-5EB22F36B1BCQ43036225-A64AA4D0-869F-418F-B0E2-11748CFBFCF6Q44511658-A52E12D7-C1FC-4CAF-8CF5-162C0B8B9974Q46496325-E6A2269B-6F94-43DB-82EF-F628FCACE6E2Q50675471-CE75997C-BF26-4286-A9B1-7151C219893AQ50754171-7B53B25E-191F-4F5E-8C0E-4ABA5F30C603Q58701325-2FBB0D2A-35C6-4409-9E7E-FE099C918256
P2860
Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Variant Creutzfeldt-Jakob dise ...... impact of deferral strategies.
@en
Variant Creutzfeldt-Jakob dise ...... impact of deferral strategies.
@nl
type
label
Variant Creutzfeldt-Jakob dise ...... impact of deferral strategies.
@en
Variant Creutzfeldt-Jakob dise ...... impact of deferral strategies.
@nl
prefLabel
Variant Creutzfeldt-Jakob dise ...... impact of deferral strategies.
@en
Variant Creutzfeldt-Jakob dise ...... impact of deferral strategies.
@nl
P2093
P2860
P1433
P1476
Variant Creutzfeldt-Jakob dise ...... impact of deferral strategies.
@en
P2093
A J Keller
J M Kaldor
P K Correll
P2860
P356
10.1046/J.1423-0410.2001.00056.X
P577
2001-07-01T00:00:00Z